Hidrosmin, a semi-synthetic flavonoid glycoside with the chemical name 5-hydroxy-7,3',4'-trimethoxyflavone glycoside (CAS: 115960-14-0), is a structurally optimized derivative of diosmin. The introduction of additional hydroxyl groups significantly enhances its bioactivity and therapeutic efficacy. Developed by Spanish pharmaceutical company Faes Farma, it is currently approved in Europe and Latin America for treating chronic venous disorders and acute hemorrhoidal episodes.
Product Name: Hidrosmin
IUPAC nominate: 5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-4H-chromen-4-one
CAS No.: 115960-14-0
